Rush to end drug rebates may be bad for patients, payers, and pharma - STAT

Rush to end drug rebates may be bad for patients, payers, and pharma - STAT

Rush to end drug rebates may be bad for patients, payers, and pharma

By IAN D. SPATZ

JOE RAEDLE/GETTY IMAGES

Eliminating rebates for prescription drugs could lead to higher prices if companies can't keep confidential the prices they negotiate for drugs.

READ MORE